PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII) today announced receipt of a $2.66 million contract for development of a therapeutic NEUGENE® antisense drug targeting dengue virus infections. This is the fourth contract related to an $11 million allocation for defense-related development of therapeutic antisense drugs, part of the 2006 Defense Appropriations Act. Under the four contracts, AVI anticipates receiving up to $9.8 million, net of government administrative costs.
